


November 21, 2022

Company Name: GNI Group Ltd. Representative: Director, Representative Executive Officer, President, and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth) Contact Person: Director, Investor Relations Akihiro Nakano (TEL. 03-6214-3600)

Amendment of "Q3 FY2022 Financial Results Corporate Presentation" document

November 21, 2022 – GNI Group Ltd., (TSE Mothers listed code: 2160) announced that it was amending "Q3 FY2022 Financial Results Corporate Presentation" document which it disclosed on November 16th, 2022, as follows. The entire document after the amendment is also attached at the end.

Amendments: P7, P19





About GNI Group, Inc.:

GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below https://www.gnipharma.com/

This material contains statements concerning the current plans, expectations, and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events, or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Group, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements. The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of GNI Group must be based on the information contained in the preliminary offering circular issued or to be issued by GNI Group in connection with any such offer and not on the contents hereof



GNI Group Ltd.

FY2022 Q3 Year to Date Financial Results Corporate Presentation

Nov 17th, 2022

CH₃

F351 CH3 F573

F647

CH₃

CH₃

Ying Luo (罗楹) President and Chief Executive Officer

Joseph Francis Meyer (J. F. マイヤー) Chief Financial Officer We Bring New Hope to Patients.





Forward-looking Statements

This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Group, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of GNI Group must be based wholly on the information contained in the preliminary offering circular issued or to be issued by GNI Group in connection with any such offer and not on the contents hereof.

This English summary translation is for reference purposes only. To the extent there is any discrepancy between this English translation and the original Japanese version, please refer to the Japanese version.




Contents





1. Multinational Operating Model

Unique Competitive Edge: GNI Platform




BAB: Berkeley Advanced Biomaterials



1. Multinational Operating Model

Cost-Efficient Platform Leveraging on China Positioning




*: Good Manufacturing Practices

Data as of :2022-11-07

2. 2022Q3 Financials 2022Q3YTD: Highly Volatile Macro Environment

Stock Price Trend Against Global Indices from 2021/12 – 2022/11



Jan

Feb

Mai

Apr

May

Jun

Jul

Aug

(Source: FactSet)

Oct

Sep



2. 2022Q3 Financials FY2022Q3YTD Consolidated Financial Results

Continue to grow while maintaining profitability and investments

Consolidated P/L	2021Q3YTD	2022Q3YTD	Change
Revenue	9,536	12,761	33.8%
Gross profit	8,327	10,853	30.3%
SG&A	5,503	7,498	36.3%
R&D	1,417	1,819	28.4%
Operating profit	1,960	1,494	-23.8%
Finance income	69	347	402.9%
Finance costs	461	618	34.1%
Profit before tax	1,568	1,223	-22.0%
Income tax expenses	693	898	29.6%
Profit after tax	874	324	-62.9%
Owner's Profit	1,294	1,076	-16.8%
FX	Change		
USD	108.55	128.02	17.9%
RMB	16.76	19.32	15.3%

	FY2021Q3	FY2022Q3	Change
Cash and cash equivalents	13,945	12,722	-8.8%
FX rates used for	Cash and cash equivalent	is	Change
USD	111.92	144.81	29.4%
RMB	17.30	20.37	17.7%

Revenues: up both reported and underlying
SG&A: Inc. JPY 125 mm one-time IPO expenses for BC

R&D: Underlying R&D up in Cullgen, down in BC

Finance income: Forex gain due to depreciation of JPY


Finance costs: Non-cash accruals for non-cash interest expense at Cullgen

Loan reduction, investments (LP, JVs), new hires

2. 2022Q3 Financials




Financial Performance Snapshot





2. 2022Q3 Financials

Consolidated Revenue Growth: 58% 10-Year CAGR



(Million JPY)

BC: Beijing Continent BAB: Berkeley Advanced Biomaterials SG: Shanghai Genomics




2. 2022Q3 Financials


GNI Group Updated Forecast for FY2022

	Revenue	Operating profit	Profit before tax	Profit for the year	Profit attributable to owners	Basic EPS
	(JPY Million)	(JPY Million)	(JPY Million)	(JPY Million)	(JPY Million)	(JPY)
Previous						
Forecast (A)	16,334	1,815	988	36	961	20.49
Revised						
Forecast (B)	18,023	2,050	1,214	35	1,217	25.65
Difference						
(B-A)	1,689	235	226	-1	256	-
Difference(%)	10.3%	12.9%	22.9%	-2.8%	26.6%	-
FY2021						
Actual	12,690	1,624	1,107	55	1,066	22.72
%Chg vs						
Previous Year	42.0%	26.2%	9.7%	-36.4%	14.2%	13%



Resilient Growth amid COVID-19 Headwinds





Pharmaceutical Segment Growth

from 2017 to Date

(Million JPY)

Note: Includes Beijing Continent, Cullgen, and Shanghai Genomics, and Reef; excludes inter-company revenue and profits



Beijing Continent's Competitive Edge

Growth engine of pharmaceutical sector

Cost-effective R&D and Manufacturing Platform

- Internal clinical development team
- Faster to market and profitability in China to sustain global product development
- Globally accepted Chinese manufacture base to produce trial drugs and commercial drugs for ROW

Nationwide Sales and Marketing Platform

- Established nationwide sales team in house for future in-licensing potential
- Close relationships with doctors and hospitals around China

Tailwinds in China

- Access to large talent pool from both returnees and local hires
- Local financial incentives improved profitability
- Double-digit growth of Chinese healthcare spending



R&D: Drug Development Pipeline (1/2) Steady progress on clinical trials in China by Beijing Continent

	Beijing Continent pharmaceutical co. Itd											
Product Indication Pre					Phase I	Phase II	Phase III	NDA	Marketed	Upcoming Milestone	Expecting approval date	Commercial Rights
	Idiopathic Pulmonary Fibrosis(IPF)		Idiopathic Pulmonary Fibrosis(IPF)							Commercialized		
	sociated	ETUARY®	Dermatomyositis Interstitial Lung disease (DM-ILD)							NDA in 2025	2025	
Pulmonary Diseases	ETUARY® (Pirfenidone)		Systemic Sclerosis-associated Interstitial Lung Disease (SSc -ILD)							NDA in 2027	2027	
Pulmona			Pneumoconiosis							NDA in 2024 Q3	2025	۲
	F528	Chronic Obstructive Pulmonary Disease (COPD)							IND in 2022 Q4	2028	۱	
	ō	F230	Pulmonary Arterial Hypertension (PAH)							IND in 2023 Q3	2028	<u>()</u>
Liver Diseases	Fibrosis	F351 (Hydronidone)	Chronic Hepatitis B Liver Fibrosis	brosis					NDA in 2024 Q2	2024	<u>)</u>	
Liver D	Other	F573	Acute Liver Failure (ALF) / Acute-on- Chronic Liver Failure (ACLF)						Phase II initiation in 2022 Q4	2025	<u>()</u>	
Kidney Disease	Fibrosis Associated	ETUARY® (Pirfenidone)	Diabetic Kidney Disease (DKD)							Phase III initiation in 2022 Q4	2027	

China Rights 💦 Global Rights 💮 Global First Right ★Rare Disease

© 2022 GN Group Ltd. All rights reserved



Cullgen's Competitive Edge

Front runner of targeted protein degradation (TPD) technology

Revolutionary Drug Discovery Platform uSMITE[™]

- Developed by TPD technology and IP pioneers
- Productive in discovering novel E3 ligands

Strong Team

- Internationally renowned scientific founders and advisors
- Leveraging Shanghai subsidiary to test in a cost-efficient way to fully understand new modalities; mitigates and reduces subsequent drug development investment risks

Renowned Financial Backers

• Financed by global venture capital funds and private equities



R&D: Drug Development Pipeline (2/2)

Multiple different promising new drug candidates in TPD under way

	cullgen									
Pr	oduct/Indication	Origin	Pre-clinical	Phase I	Phase II	Phase III	Latest Status 2022.09			
Cancer	TRK degrader CG001419 (China)	Proprietary					IND [#] for Phase 1 clinical trial approved by China's NMPA [*] . Preparing for trial launch.			

Active Dialogue with US FDA for bridging study

Product/Indication		Origin	Phase I	Phase II	Phase III	Latest Status 2022.07			
Liver Fibrosis (NASH)	F351(USA)	Proprietary				Under pre-IND discussions with FDA for NASH ⁺ Phase II clinical trial in the US			

*NMPA: National Medical Products Administration #IND: Investigational New Drug *NASH: Non-Alcoholic SteatoHepatitis




4. Biomaterial/Medical Device Pillar

Medical Device Segment: Stable Cash Generation

16.64

FX rate (RMB)

- ✓ Steady Econ value add in the US
 ✓ Expansion overseas using proprietary components for aesthetics
- Entry into DMAH* business in Japan



(Million JPY)

19.56

*DMAH: Designated Marketing Authorization Holder

Note: Includes Berkeley Advanced Biomaterials; excludes inter-company revenue and profits

15.85

15.44

17.02

16.69



4. Biomaterial/Medical Device Pillar

Berkeley Advance Biomaterials' (BAB) Competitive Edge

Stable performance with new product potential

Stable Industry

- Least volatile product cycle in medical device industry
- Lower regulatory risk hurdles than in drug development

Great Potential

- Expanding to aesthetics market internationally
- Diversifying against unforeseeable geopolitical risks

Excellent Risk-Return Profile

• Good investment return with future pipeline



GNI Group 2023 Strategic Goals

Finish enrollment of patients for F351 liver fibrosis clinical trials

List Beijing Continent in a major stock exchange

Expand biomaterial business into new growth area


Build up Japan operation step by step

Support Cullgen to lead cancer drug discovery

Increase profitability of GNI Group




GNI Group Organization





New Area of Growth of Biomaterial Business: Aesthetics



来源:艾瑞咨询研究院根据公开数据、企业财报、专家访谈、艾瑞独立数据建模核算及绘制。



Continuing Efforts in ESG

- BC holds GB/T24001:2016^{*} Certificate
- BC's expenditure on environmental protection to contain toxic emissions and waste disposal up 50% from 2019 to 2021

- BC's donation of ETUARY to NPO in China up 7.8% YoY
- BAB holds ISO 13485:2016⁺ Certificate
- Regular inspections at BC manufacturing facility to ensure safety

- Targeting to further diversify GNI board membership in 2023
- GNI and BC adopt committee systems in the board

Environment

Social



Governance

* GB/T24001: Chinese name for ISO 14001 on environmental management system standard + ISO 13485:2016: International standard for quality management in medical device industry



Contact Information

infojapan@gnipharma.com